-
Mashup Score: 11
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous…
Source: www.globenewswire.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication - 2 month(s) ago
Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications,…
Source: www.globenewswire.comCategories: General Medicine News, Expert PicksTweet-
Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication https://t.co/DvkZ3hSgN4
-
-
Mashup Score: 1Cellenkos Presents Phase 1b Data at ASH 2024 Showcasing the Potential of T-Regulatory Cell Therapy Candidate CK0804 for Myelofibrosis - 2 month(s) ago
– Safety profile established and encouraging efficacy signals demonstrated by reductions in spleen volume and symptom burden scores – Data underscore the…
Source: www.globenewswire.comCategories: General Medicine News, Oncologists1Tweet-
https://t.co/FeRDKtxpxY
-
-
Mashup Score: 14
IGI Presents 1st Clinical Data from Ph 1 Study of Trispecific Antibody, ISB 2001, Showing High ORR & Favorable Safety Profile in Heavily Treated RRMM Pts….
Source: www.globenewswire.comCategories: General Medicine News, Hem/OncsTweet-
First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma https://t.co/2tt2WpDw7t #ASH24 @ASH_hematology… https://t.co/3DhLdfthYR
-
-
Mashup Score: 5Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP - 2 month(s) ago
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP Pivotal phase 3 data show rapid…
Source: www.globenewswire.comCategories: General Medicine News, Hem/OncsTweet-
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP https://t.co/zswiV6G3Or
-
-
Mashup Score: 0
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing…
Source: www.globenewswire.comCategories: General Medicine News, Rare DiseaseTweet-
Lucky petrie dishes... https://t.co/UGMDFY7yRx
-
-
Mashup Score: 8
LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and…
Source: www.globenewswire.comCategories: General Medicine News, Rare DiseaseTweet-
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND https://t.co/UFUfK6QvnQ
-
-
Mashup Score: 0Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication - 2 month(s) ago
Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications,…
Source: www.globenewswire.comCategories: General Medicine News, Expert PicksTweet-
Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication https://t.co/DvkZ3hSgN4
-
-
Mashup Score: 1
First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in…
Source: www.globenewswire.comCategories: General Medicine News, Oncologists1Tweet-
🚨 NEWS 🚨 First patient dosed in the phase I/II multicenter, open-label DAHLIA trial of REC-1245, a selective RBM39 degrader, for the treatment of patients with #lymphoma and biomarker-enriched solid tumors. Read more here: https://t.co/NwJ3THXmSY #lymsm #MedNews https://t.co/0lQGZ8fKKY
-
-
Mashup Score: 1
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials…
Source: www.globenewswire.comCategories: General Medicine News, Oncologists1Tweet-
🚨NEWS🚨 @EMA_News has granted PRIME designation to NX-5948, a selective BTK degrader, for the treatment of patients with R/R CLL/SLL who have received at least a BTK inhibitor and a BCL-2 inhibitor. Read more: https://t.co/MIsgxqzg2M #lymphoma #CLL #lymsm #mednews https://t.co/anslUC0mmh
-
🚨 NEWS 🚨 An application has been submitted to the @EMA requesting an indication extension for ibrutinib in combination with R-CHOP for adults with untreated MCL who are eligible for ASCT, based on data from TRIANGLE trial. 👉 https://t.co/IFRpFnfbB8 #lymsm #lymphoma #MedNews https://t.co/ze9aXdj3TK